TABLE 4.

Final consensus statements

	Median Likert score	% agreement	Strength of recommendation
Overarching principles
Vaccination in people with rheumatic diseases should be aligned with prevailing national policy.	4.5	100	‐
The decision for vaccination should be individualized, and should be explained to the patient, to provide a basis for shared decision‐making between the healthcare provider and the patient.	5	100	‐
Recommendations
1. We strongly recommend that eligible patients be vaccinated against SARS‐CoV2.	5	100	Strong
2. We conditionally recommend that the COVID‐19 vaccine be administered during quiescent disease, if possible.	4.5	100	Conditional
3. We conditionally recommend that immunomodulatory drugs, other than rituximab, can be continued alongside COVID‐19 vaccination.	5	80	Conditional
4. We conditionally recommend that the COVID‐19 vaccine be administered prior to commencing rituximab, if possible. For patients on rituximab, the vaccine should be administered a minimum of 6 mo after the last dose, and/or 4 wk prior to the next dose of rituximab.	4	90	Conditional
5. We conditionally recommend that post‐COVID‐19 vaccination antibody titers need not be measured.	4	90	Conditional
6. We strongly recommend that household contacts be vaccinated against SARS‐CoV2.	4.5	100	Strong
7. We conditionally recommend that any of the approved COVID‐19 vaccines may be used, with no particular preference.	4	70	Conditional

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.